zurück

Olaparib (new indication: metastatic castration-resistant prostate cancer (mCRPC) in combination with abiraterone and/or prednisone for patients in whom chemotherapy is not clinically indicated)

 

Subject:

  • Active Substance: Olaparib
  • Name: Lynparza®
  • Therapeutic area: Prostate cancer
  • Pharmaceutical company: AstraZeneca GmbH

 

Time table:

  • Start: 15.01.2023
  • Publication of assessment: 17.04.2023
  • End of public hearing: 08.05.2023
  • Final decision by G-BA: beginning of July 2023

 

Comparative therapy:

  1. Therapy-naïve patients: therapy at the physician’s discretion choosing from abiraterone acetate in combination with prednisone or prednisolone OR enzalutamide.

  2. Pre-treated patients: a patient-individual therapy taking into account prior therapy and BRCA1/2 mutation status choosing from abiraterone acetate in combination with prednisone or prednisolone OR enzalutamide OR olaparib.